CONTEXT THERAPEUTICS INC (CNTX)

Company Profile

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2021-10-20. The firm is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors. Its preclinical program, CTIM-76, is an anti-Claudin 6 x anti-CD3 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, lung, and testicular, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is a Claudin 6 and CD3 bispecific antibody capable of binding to tumor cells expressing Claudin 6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement. Claudin 6 is expressed on multiple solid tumors such as ovarian, lung and testicular.

Company Info

CONTEXT THERAPEUTICS INC

2001 Market Street, Suite 3915 Unit #15

PHILADELPHIA PENNSYLVANIA

P: 12672257416

Employees: 9

Website: https://www.contexttherapeutics.com/